EyePoint Pharmaceuticals (EYPT) Expected to Announce Quarterly Earnings on Wednesday

EyePoint Pharmaceuticals (NASDAQ:EYPT) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $11.02 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $5.72 on Tuesday. The business’s 50-day moving average is $7.31 and its two-hundred day moving average is $8.50. The company has a market capitalization of $390.40 million, a P/E ratio of -2.86 and a beta of 1.51. EyePoint Pharmaceuticals has a fifty-two week low of $5.67 and a fifty-two week high of $27.84.

Analyst Ratings Changes

EYPT has been the topic of several analyst reports. Robert W. Baird cut their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Citigroup initiated coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 price target on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.